Eli Lilly Set to Top Big Pharma in 2024, While Novo Nordisk Faces Challenges Despite Obesity Drug Presence
Eli Lilly is projected to outshine its Big Pharma peers in 2024, thanks to robust performance in the weight loss drug market, with Zepbound taking the lead. Novo Nordisk, however, is expected to face hurdles despite its stronghold with Wegovy, revealing a dynamic tug-of-war in the pharmaceutical world. This shift highlights changing competitive landscapes driven by drug efficacy, market conditions, and strategic investments.
Dec 31